Works matching IS 15268209 AND DT 2024 AND VI 24 AND IP 7


Results: 10
    1

    A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.

    Published in:
    Clinical Breast Cancer, 2024, v. 24, n. 7, p. 639, doi. 10.1016/j.clbc.2024.07.001
    By:
    • Kothari, Rushabh;
    • Doshi, Maulik;
    • Chaithanya, R. K.;
    • C. T., Satheesh;
    • Kumar, Anil;
    • Mallavarapu, Krishna Mohan;
    • Nagarkar, Rajnish;
    • Mahobia, Vijay;
    • Bhatt, Niraj;
    • Priyadarshini, K. L.;
    • Gogia, Ajay;
    • Maksud, Tanveer;
    • Prasad, Saurabh;
    • Velavan, K.;
    • L. K., Rajeev;
    • S.S., Prakash;
    • Talreja, Vikas;
    • Kalra, Kaushal;
    • Nemade, Bhushan;
    • Dastidar, Aloke Ghosh
    Publication type:
    Article
    2

    The Genomic Landscape of Breast Cancer in Young and Older Women.

    Published in:
    Clinical Breast Cancer, 2024, v. 24, n. 7, p. 630, doi. 10.1016/j.clbc.2024.07.008
    By:
    • Heeke, Arielle L.;
    • Wei Sha;
    • Feldman, Rebecca;
    • Fisher, Julie;
    • Hadzikadic-Gusic, Lejla;
    • Symanowski, James T.;
    • White Jr, Richard L.;
    • Tan, Antoinette R.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10